Diabetes, Metabolic Syndrome and Cardiovascular Disease : Market Research Report

Diabetes, Metabolic Syndrome and Cardiovascular Disease

Published: Apr. 1, 2009 - 265 Pages

1. Overview: 1.1 Statement of Report; 1.2 About this Report; 1.3 Scope of the Report; 1.4 Methodology; 1.5 Executive Summary
2. Introduction: 2.1 Demographics of Diabetes; 2.2 Economics of Diabetes
3. Understanding the Metabolic Conditions Underlying and Associated with Diabetes: 3.1 Pre-Diabetes Syndrome; 3.2 Metabolic Syndrome; 3.3 Diabetes and Inflammation; 3.4 Progression of Diabetes; 3.5 Complications and Co-Morbidities in Type 2 Diabetes; 3.6 Hypoglycemia and Treatment; 3.7 Risk Factors and Diabetes; 3.8 Cardiovascular Disease (CVD) Facts
4. Pharmaceutical Industry and the Anti-Diabetes Market: 4.1 The Worldwide Pharmaceutical Industry; 4.2 Total Diabetes Drug Market Size and Growth; 4.3 Epidemiology/Cost of Treatment; 4.4 Diabetic Medications Overview
5. Non-Insulin Anti-Diabetes Products: 5.1 Anti-Diabetic Drug Therapy Overview; 5.2 Drivers and Trends; 5.3 The Future; 5.4 Anti-Diabetic Drug Patent Expiry; 5.5 Regulatory Issues
6. Insulin: 6.1 Insulin Markets; 6.2 Insulin and Analogs; 6.3 Insulin Analogs; 6.4 Non-Insulins in Development; 6.5 Pipeline Insulin; 6.6 Non-Invasive Insulin Delivery; 6.7 Barriers for Non-Injected Insulin; 6.8 Patient Potential for Non-Injected Insulin; 6.9 Insulin Delivery Devices; 6.10 Market Forecasts for Insulin Administration Technologies
7. Emerging Anti-Diabetes Products: 7.1 Projections for the Anti-Diabetes Drug Market; 7.2 Artificial Pancreas; 7.3 Insulin-Producing Cells; 7.4 Transplantation Procedures; 7.5 Gastric Bypass Surgery to Treat Type 2 Diabetes; 7.6 Immune Modulators; 7.7 Anti-Obesity Drug Xenical to Prevent or Delay Development of Type 2 Diabetes; 7.8 Other Anti-Diabetic Therapy Drug Candidates; 7.9 Drugs Used “Off-Label”; 7.10 Pipeline Diabetic Drug Candidates; 7.11 Drug Research Overview; 7.12 Future Anti-Diabetic Drugs in Late-Stage Development
8. Diagnosing Diabetes Using In Vitro Laboratory Tests: 8.1 New Diagnostic Guidelines; 8.2 Diabetes Tests; 8.3 Glucose Monitoring
9. Market Trends, Challenges and Strategic Options: 9.1 Overview; 9.2 Diabetes Drug Market Trends; 9.3 Diabetes Mellitus Market Challenges; 9.4 Strategic Options; 9.5 FDA Therapeutic Targets; 9.6 Outlook to Anti-Diabetes Drugs; 9.7 Outlook for Cardiovascular Drugs
10. Company Profiles: 10.1 A. Menarini; 10.2 Abbott Laboratories; 10.3 Amgen; 10.4 AstraZeneca; 10.5 Bayer; 10.6 BodyMedia; 10.7 Cybermedical; 10.8 Debiotech; 10.9 DexCom; 10.10 Echo Therapeutics; 10.11 Elixir Pharmaceuticals; 10.12 Eksigent; 10.13 Flamel Technologies; 10.14 GlaxoSmithKline; 10.15 GlucoLight; 10.16 Insulet; 10.17 iSense Corporation; 10.18 Isis Pharmaceuticals, Inc.; 10.19 Johnson & Johnson; 10.20 KYORIN; 10.21 M-Biotech; 10.22 Medtronic; 10.23 Merck & Co.; 10.24 Merck KGaA; 10.25 MicroIslet; 10.26 Mitsubishi Tanabe Pharma Corporation; 10.27 Nipro Diabetes Systems; 10.28 Novartis; 10.29 Novo Nordisk; 10.30 Novocell; 10.31 ONO Pharmaceutical; 10.32 Orexigen Therapeutics; 10.33 Pfizer; 10.34 ReNeuron; 10.35 Roche Diagnostics; 10.36 Sanofi-Aventis; 10.37 Sensors for Medicine and Science; 10.38 Siemens; 10.39 Smiths Medical; 10.40 Servier; 10.41 SOOIL Development; 10.42 Takeda; 10.43 TheraFuse; 10.44 Teco Diagnostics; 10.45 Transition Therapeutics; 10.46 U.S. Diagnostics; 10.47 VeraLight; 10.48 Vivus; 10.49 Ypsomed Holding
Appendix 1: Contact Information for Companies Profiled
Appendix 2: Prescribing Patterns for Anti-Hyperglycemic Drugs
Appendix 3: Detailed List of Insulins Available
Appendix 4: The History of Insulin
Appendix 5: Diabetes and Obesity Drugs in Development
Appendix 6: Pharmaceutical Sampling Practices
INDEX OF FIGURES: Figure 2.1: Worldwide Rates of Diabetes Cases, 2000-2025; Figure 2.2: Prevalence of Diabetes by Age in the U.S, 2007; Figure 2.3: New Adult Cases of Diabetes Diagnosed in the U.S., 2007; Figure 2.4: Distribution of Duration of Diabetes among Adults Aged 18 to 79 Years in the U.S., 2005; Figure 2.5: Number of Persons with Diagnosed Diabetes in the U.S., 1980-2007; Figure 2.6: Treatment with Insulin or Oral Medication among Adults Diagnosed with Diabetes, 2007; Figure 2.7: Rate of New Diabetes Cases among Children in the U.S., 2007; Figure 2.8: Expenditure Associated with Diabetes Complications in the U.S., 2007; Figure 2.9: Diabetes Death Rate by Race and Sex in the U.S., 1979-2006; Figure 3.1: Prevalence of Complications in Diabetics vs. People with Normal Blood Sugar Levels, 2007; Figure 3.2: Per Capita Costs for Diabetes-related Complications per Year, 2007; Figure 3.3: Total Spending on Healthcare in the U.S., 1960-2008; Figure 3.4: Percentage Breakdown of U.S. Healthcare Spending, 2008; Figure 3.5: Percentage of U.S. Population that Smokes, 1965-2005; Figure 3.6: Heart Disease Death Rate by Race and Sex in the U.S., 1979-2006; Figure 3.7: Hypertension Drugs Newly Prescribed or Continued in the U.S., 1994-2007; Figure 3.8: Annual Death Rate of U.S. Population from Strokes, 1950-2008; Figure 3.9: U.S. Male and Female Population Death Rates from Strokes, 2008; Figure 3.10: Annual Death Rate of U.S. Population from Heart Disease, 1950-2008; Figure 3.11: Percentage of U.S. Population that is Overweight, 1976-2004; Figure 4.1: Medical Research in the U.S. Outpaces the Rest of the World; Figure 4.2: Cost of Diabetes in the U.S., 2007; Figure 4.3: Top Therapeutic Classes Contributing to Drug Trend, 2007; Figure 4.4: U.S. Non-Insulin Anti-Diabetic Drug Prescriptions, 2006; Figure 5.1: Comparison of the Effects of the Pioglitazone and Rosiglitazone on Lipids; Figure 5.2: U.S. Non-Insulin Anti-Diabetes Sales, 2006; Figure 5.3: Sales Forecast for the Global Diabetes Market, 1992-2012; Figure 6.1: Insulin Pump Market Share, 2007; Figure 6.2: Relative Risk of Diabetes Complications by Mean HbA1c; Figure 9.1: Relationship between Diabetes Therapy and the Proposed Timeline; Figure A3.1: Novo Nordisk’s Rising Market Share in the U.S. Insulin Market, 1982-2008
INDEX OF TABLES: Table 1.1: Criteria for the Diagnosis of Diabetes; Table 2.1: Top Ten Countries in Number of Diabetics (20 to 79 Age Group) in the; World, 2007 and 2025; Table 2.2: Annual Estimated Cost of Diabetes Care in the U.S., 2007; Table 2.3: Impact of Diabetes on Americans; Table 2.4: How Diabetes Dollars are Spent in the U.S., 2007; Table 3.1: Percentage of GDP Healthcare Spending by Country, 2008; Table 3.2: Life Expectancy Rate by Country, 2008; Table 3.3: Normal Glucose Values—Fasting State; Table 3.4: Percentage of Adults Smokers by Country, 2008; Table 3.5: Worldwide Market for Cardiac Care Therapeutics, 2003-2010; Table 3.6: Death Rate from Cardiovascular Diseases by Country, 2008; Table 4.1: Leading Therapy Classes for R&D, 2008; Table 4.2: Pharmaceutical R&D Expenditures by World Region, 1990-2007; Table 4.3: Pharmaceutical Companies Ranked by Total R&D Expenditures, 2007; Table 4.4: Global Pharmaceutical Sales, 2007; Table 4.5: World Pharmaceutical Sales Share by Region, 2007; Table 4.6: The World’s Top-Selling Drugs (Audited Market), 2007; Table 4.7: Pharmaceutical Product Sales by Country Market, 2007; Table 4.8: Top Ten Global Pharmaceutical Companies by Global Sales, 2007; Table 4.9: Leading Therapy Classes by Global Pharmaceutical Sales (Audited Market), 2007; Table 4.10: Leading Ten Therapeutic Classes by U.S. Sales, 2003-2007; Table 4.11: Top Ten Therapeutic Classes by U.S. Dispensed Prescriptions, 2006 and 2007; Table 4.12: Top Ten Brand Drugs by U.S. Retail, 2007; Table 4.13: Worldwide Anti-Diabetes Drug Market, 2006-2012; Table 4.14: Oral Anti-Diabetic Therapy Major World Markets, 2006; Table 4.15: The Leading Ten Anti-Diabetics by Sales, 2007; Table 4.16: Non-Insulin Hypoglycemic Drugs Used to Treat Type 2 Diabetes, 2008; Table 4.17: Summary of Glucose-Lowering Interventions as Monotherapy; Table 5.1: Classes of Non-Insulin Hypoglycemic Agents; Table 5.2: Average Dose and Cost Comparison of Hypoglycemic Agents; Table 5.3: Relative Efficacy of Diabetes Drugs; Table 5.4: Thiazolidinediones Available for Type 2 Diabetes Mellitus; Table 5.5: Fixed Drug Combinations; Table 5.6: GLP-1 Pipeline: Selected Drugs in Development that Target GLP-1; Table 5.7: DPP-IV Inhibitor Pipeline; Table 6.1: Available Therapeutic Insulin Alternatives; Table 6.2: Worldwide Insulin Sales, 2005-2012; Table 6.3: Worldwide Insulin Sales and Market Share by World Region, 2007; Table 6.4: Worldwide Insulin Sales and Market Share by Company, 2007; Table 6.5: U.S. Insulin Sales and Market Share by Company, 2007; Table 6.6: U.S. Retail Insulin Sales, 2006-2009; Table 6.7: Comparison of Rapid-Acting Insulins; Table 6.8: Comparison of Long-Acting Insulins; Table 6.9: Pharmacokinetics of Available Insulins; Table 6.10: Status of Inhaled Insulin Products, 2009; Table 6.11: Key Drivers of the Type 2 Diabetes Insulin Market, 2012; Table 6.12: A Comparison of Existing Insulin Delivery Devices; Table 6.13: Lancet Characteristics; Table 6.14: Lancing Device Characteristics; Table 6.15: Insulin Pens; Table 6.16: Worldwide Demand for Insulin Injector Pens by Volume, 2006-2010; Table 6.17: Injection Aids; Table 6.18: Jet Injectors; Table 6.19: Leading Insulin Pump Manufacturers; Table 6.20: External Insulin Pumps; Table 6.21: Comparison of Current Insulin Pumps on the Market; Table 6.22: Control Averages by Treatment; Table 6.23: Reduced Risk for Various Diseases When Blood Glucose is Near Normal; Table 6.24: Worldwide Diabetes Market, 2008; Table 6.25: Types of Insulin Pumps on the Market; Table 7.1: Advantages and Disadvantages of Newer Type 2 Diabetes Therapies; Table 7.2: Cells of the Pancreas; Table 7.3: Lipoprotein Risk Levels and Treatment Goals in Adult Patients with Diabetes; Table 7.4: Agents for Lowering Lipid Levels in Patients with Dyslipidemia; Table 7.5: Suggested Pharmacological Treatment Agents for Hypertension in Patients with Diabetes; Table 7.6: Selected Mid-2008 Press Releases on Emerging Anti-Diabetes Agents; Table 7.7: Diabetes Agents in the Pipeline; Table 7.8: Future Anti-Diabetic Drugs in Late-Stage Development; Table 8.1: Laboratory Assessment of Diabetic Vascular Disease; Table 8.2: Worldwide Market for Diabetes Self-Testing (Meters, Strips and Lancets), 2004-2012; Table 8.3: Market for Glucose Self-Testing in the U.S., 2004-2012; Table 8.4: U.S. Sales for OTC Blood Glucose Meters and Strips, 2007; Table 9.1: BRIC countries, Percentage of GDP Spent on Healthcare, 2008; Table 9.2: Selected Licensing Deals in the Diabetes Arena, 2003-2008; Table 9.3: Top Therapeutic Categories in U.S. Development, 2008; Table 9.4: Pharmaceutical Companies by Number of Products in R&D Pipeline, 2007; Table 9.5: Pharmaceutical Companies by Number of Diabetes Products in Development; Table 9.6: Selected New Diabetes Drugs in Pipeline, 2007; Table 9.7: Comparison of New Molecular Entity Outcomes for FDA and EMEA (Jan 2006 to October 2008); Table 9.8: Upcoming Milestones for Selected Diabetes Drugs; Table 9.9: Overview of Blockbuster Drugs Coming Off-Patent, 2008 to 2012; Table A1.1: Company Headquarters Contact Information; Table A3.1: Current Insulins; Table A4.1: Select Archived Press Release Excerpts; Table A5.1: The Diabetes/Obesity Pipeline by Developmental Stage, 2009

Abstract

There has been a dramatic increase in the incidence of diabetes worldwide, which has been exacerbated by the growing obesity problem across the globe. Once thought of as primarily a childhood disease--sometimes referred to as juvenile diabetes, now mostly Type 1 diabetes--the obesity crisis linked to the adoption of a high-fat, high-carbohydrate, high-calorie American diet has resulted in skyrocketing rates of diabetes among adults across the world. To compound the global diabetes epidemic, health professionals are witnessing an alarming increase in inflammatory diseases resulting from adult onset (i.e., Type 2) diabetes. This phenomenon is referred to as "metabolic syndrome" where a confluence of inflammatory conditions occur along with the diabetes. As a result, growing evidence appears to show that metabolic syndrome makes the diabetic patient susceptible to degenerative health conditions such as cardiovascular disease, stroke and, now believed, Alzheimer's disease. As the diabetes epidemic escalates, a new sense of urgency has taken hold. Proactive strategies for prevention of the disease are being put in place by international health organizations such as the World Health Organization (WHO), as well as by the health departments of industrialized and developing countries, and even at the local level where food ingredients regulations are being passed. This TriMark Publications report charts the changing landscape of the global diabetic population and explores the added health concerns resulting from the metabolic syndrome phenomenon and one of its major risk factors: cardiovascular disease (CVD). Furthermore, this study evaluates widely-accepted therapeutic approaches to diabetes that are currently in use, while providing an in-depth analysis of emerging technologies that will be used to treat diabetes and other inflammatory diseases in the future.

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

Diabetes, Metabolic Syndrome and Cardiovascular Disease

Table of Contents

Abstract